Chapter 8
Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis
P. Soelberg Sørensen,
F. Deisenhammer,
P. Duda,
R. Hohlfeld,
K.-M. Myhr,
J. Palace,
C. Polman,
C. Pozzilli,
C. Ross,
P. Soelberg Sørensen
Copenhagen Danish Multiple Sclerosis Research Center, Neuroscience Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Search for more papers by this authorF. Deisenhammer
Department of Neurology, University of Innsbruck, Innsbruck, Austria
Search for more papers by this authorP. Duda
Outpatient Clinic Neurology-Neurosurgery, University Hospitals, Basel, Switzerland
Search for more papers by this authorR. Hohlfeld
Institute for Clinical Neuroimmunology, University of Munich, Klinikum Grosshadern, Munich, Germany
Search for more papers by this authorK.-M. Myhr
Department of Neurology, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorJ. Palace
Multiple Sclerosis Group, Radcliffe Infirmary, Oxford, UK
Search for more papers by this authorC. Polman
Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands
Search for more papers by this authorC. Pozzilli
Department of Neurological Sciences, II Faculty of Medicine, University “La Sapienza”, Rome, Italy
Search for more papers by this authorC. Ross
Institute for Inflammation Research, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Search for more papers by this authorP. Soelberg Sørensen,
F. Deisenhammer,
P. Duda,
R. Hohlfeld,
K.-M. Myhr,
J. Palace,
C. Polman,
C. Pozzilli,
C. Ross,
P. Soelberg Sørensen
Copenhagen Danish Multiple Sclerosis Research Center, Neuroscience Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Search for more papers by this authorF. Deisenhammer
Department of Neurology, University of Innsbruck, Innsbruck, Austria
Search for more papers by this authorP. Duda
Outpatient Clinic Neurology-Neurosurgery, University Hospitals, Basel, Switzerland
Search for more papers by this authorR. Hohlfeld
Institute for Clinical Neuroimmunology, University of Munich, Klinikum Grosshadern, Munich, Germany
Search for more papers by this authorK.-M. Myhr
Department of Neurology, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorJ. Palace
Multiple Sclerosis Group, Radcliffe Infirmary, Oxford, UK
Search for more papers by this authorC. Polman
Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands
Search for more papers by this authorC. Pozzilli
Department of Neurological Sciences, II Faculty of Medicine, University “La Sapienza”, Rome, Italy
Search for more papers by this authorC. Ross
Institute for Inflammation Research, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Search for more papers by this authorBook Editor(s):Richard Hughes,
Michael Brainin,
Nils Erik Gilhus,
Richard Hughes
Professor of Neurology, Department of Clinical Neuroscience, King's College London, London, UK
Search for more papers by this authorMichael Brainin
Professor of Clinical Neurology, Donauklinikum Gugging and Donau-Universität, Krems, Austria
Search for more papers by this authorNils Erik Gilhus
Professor of Neurology, University of Bergen and Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorSummary
This chapter contains section titled:
-
Abstract
-
Background and objectives
-
Search strategy and consensus
-
Immunogenicity
-
Measurements of binding and neutralizing antibodies
-
Clinical use of measurements of antibodies against IFNβ
-
Prevention and treatment of NABs
-
Principal recommendations regar-ding measurements of antibodies against IFNβ and the clinical use of NAB measurements
References
- Abdul-Ahad AK, Galazka AR, Revel M, Biffoni M, Borden EC (1997). Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. Cytokines Cell Mol Ther 3: 27–32.
- Antonelli G, Simeoni E, Bagnato F et al. (1999). Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci 168: 131–136.
- Bellomi F, Scagnolari C, Tomassini V et al. (2003). Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 215: 3–8.
- Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R (2000). Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 48: 95–100.
- Bertolotto A, Malucchi S, Sala A, et al. (2002). Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73: 148–153.
- Bertolotto A, Gilli F, Sala A et al. (2003). Persistent neutralizing antibodies abolish the interferon beta bioavail-ability in MS patients. Neurology 60: 634–639.
- Brainin M, Barnes M, Baron JC et al. (2004). Guidance for the preparation of neurological management guidelines by EFNS scientific task forces?revised recommendations 2004. Eur J Neurol 11: 577–581.
- Calabresi PA, Wilterdink JL, Rogg JM, Mills P, Webb A, Whartenby KA (2002). An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 58: 314–317.
- Clanet M, Radue EW, Kappos L et al. (2002). A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59: 1507–1517.
- Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T (1999). Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52: 1239–1243.
- Dresser DW, Mitchison NA (1968). The mechanism of immunological paralysis. Adv Immunol 8: 129–181.
- Dubois BD, Keenan E, Porter BE et al. (2003). Inter-feron beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 74: 946–949.
-
Dummer R,
Muller W,
Nestle F et al.
(1991).
Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients.
Cancer
67:
2300–2304.
10.1002/1097-0142(19910501)67:9<2300::AID-CNCR2820670916>3.0.CO;2-A CAS PubMed Web of Science® Google Scholar
- Durelli L, Verdun E, Barbero P et al. (2002). Every-other-day interferon beta-1b versus once-weekly inter-feron beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359: 1453–1460.
- European Study Group on interferon beta-1b in secondary progressive MS (1998). Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352: 1491–1497.
- Fernandez O, Mayorga C, Luque G et al. (2001). Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients. J Neurol 248: 383–388.
- Fernandez O, Guerrero M, Mayorga C et al. (2002). Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study. J Neurol 249: 1058–1062.
- Ferrarini AM, Sivieri S, Buttarello M, Facchinetti A, Perini P, Gallo P (1998). Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferonbeta 1b-treated multiple sclerosis patients. Mult Scler 4: 174–177.
- Fierlbeck G, Schreiner T, Schaber B, Walser A, Rassner G (1994). Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta. Cancer Immunol Immunother 39: 263–268.
- Gneiss C, Reindl M, Lutterotti A et al. (2004). Interferonbeta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler 10: 507–510.
- Grossberg SE, Kawade Y, Kohase M, Klein JP (2001a). The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 21: 743–755.
- Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N (2001b). The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 21: 729–742.
- Jacobs LD, Cookfair DL, Rudick RA et al. (1996). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39: 285–294.
- Kageshita T, Yamamoto A, Yamazaki N, Ishihara K, Ono T (1999). Low frequency of neutralizing antibodies against natural interferon-beta during adjuvant therapy for Japanese patients with melanoma. J Dermatol Sci 19: 208–212.
- Khan OA, Dhib-Jalbut SS (1998). Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology 51: 1698–1702.
- Kivisakk P, Alm GV, Fredrikson S, Link H (2000). Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol 7: 27–34.
- Kob M, Harvey J, Schautzer F et al. (2003). A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta. Mult Scler 9: 32–35.
- Kremenchutzky M (2003). Long-term evolution of anti-INFbeta antibodies in IFNbeta-treated MS patients: the London, Canada, MS Clinic experience. Neurology 61: S29–S30.
- Larocca AP, Leung SC, Marcus SG, Colby CB, Borden EC (1989). Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser. J Interferon Res 9 (Suppl 1): S51–S60.
- Lampasona V, Rio J, Franciotta D, Furlan R, Avolio C, Fazio R, Lavolpe V, Vincent A, Comi G, Trojano M, Montalban X, Martino G (2003). Serial immuno-precipitation assays for interferon-(IFN)-beta antibodies in multiple sclerosis patients. Eur Cytokine Netw 14: 154–157.
- Lawrence N, Oger J, Aziz T, Palace J, Vincent A (2003). A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta. J Neurol Neurosurg Psychiatry 74: 1236–1239.
- Li DK, Zhao GJ, Paty DW (2001). Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 56: 1505–1513.
- Mayr M, Berek K, Deisenhammer F (2003). Evolution of interferon-beta binding antibodies in MS patients may predict development of neutralizing antibodies. Eur J Neurol 10: 462–464.
- Monzani F, Meucci G, Caraccio N et al. (2002). Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis. J Interferon Cytokine Res 22: 773–781.
-
Pachner AR,
Narayan K,
Price N,
Hurd M,
Dail D
(2004).
MxA Gene Expression Analysis as an Interferon-beta Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity.
Mol Diag
7:
17–25.
10.2165/00066982-200307010-00004 Google Scholar
- Panitch H, Goodin DS, Francis G et al. (2002). Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59: 1496–1506.
- Patti F, Cataldi ML, Nicoletti F et al. (2001). Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 71: 404–407.
- Perini P, Facchinetti A, Bulian P et al. (2001). Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 12: 56–61.
- Perini P, Calabrese M, Biasi G, Gallo P (2004). The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 251: 305–309.
- Polman C, Kappos L, White R et al. (2003a). Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 60: 37–43.
- Polman CH, Kappos L, Petkau J, Thompson A (2003b). Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 74: 1162–1163.
- Pozzilli C, Antonini G, Bagnato F et al. (2002). Monthly corticosteroids decrease neutralizing antibodies to IFN-beta1 b: a randomized trialinmultiple sclerosis. J Neurol 249: 50–56.
- PRISMS (Prevention of Relapses and Disability by Inter-feron beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998). Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352: 1498–1504.
- PRISMS Study Group (2001). PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56: 1628–1636.
- Prummer O, Bunjes D, Wiesneth M et al. (1996). Antibodies to interferon-alpha: a novel type of autoantibody occurring after allogeneic bone marrow transplantation. Bone Marrow Transplant 17: 617–623.
- Pungor E, Files JG, Gabe JD et al. (1998). A novel bioassay for the determination of neutralizing antibodies to IFN-ß1b. J Interferon Cytokine Res 18: 1025–1030.
- Redlich PN, Grossberg SE (1989). Analysis of antigenic domains on natural and recombinant human IFN-ß by the inhibition of biologic activities with monoclonal antibodies. J Immunol 143: 1887–1893.
- Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G (1999). The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 52: 1277–1279.
- Ross C, Clemmesen KM, Svenson M et al. (2000). Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 48: 706–712.
- Rudick RA, Goodkin DE (1999). Multiple Sclerosis Therapeutics. Martin Dunitz, London, pp. 309–333.
- Rudick RA, Simonian NA, Alam JA et al. (1998). Incidence and significance of neutralizing antibodies to inter-feron beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50: 1266–1272.
- Runkel L, Meier W, Pepinsky RB et al. (1998). Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 15: 641–649.
- Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group (2001). Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 56: 1496–1504.
- Slavikova M, Schmeisser H, Kontsekova E, Mateicka F, Borecky L, Kontsek P (2003). Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia. J Interferon Cytokine Res 23: 143–147.
- Sorensen PS, Ross C, Clemmesen KM et al. (2003). Clinical importance of neutralising antibodies against inter-feron beta in patients with relapsing-remitting multiple sclerosis. Lancet 362: 1184–1191.
- Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K (2005). Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65: 33–99.
- The IFNB Multiple Sclerosis Study Group (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661.
- The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1996). Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47: 889–894.
- The North American Study Group on interferon beta-1b in Secondary Progressive MS (2004). Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology 63: 1788–1795.
- Vallittu AM, Halminen M, Peltoniemi J et al. (2002). Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients. Neurology 58: 1786–1790.
- von Wussow P, Jakschies D, Freund M, Deicher H (1989). Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy. J Interferon Res 9 (Suppl 1): S25–S31.
- Zang YC, Yang D, Hong J, Tejada-Simon MV, Rivera VM, Zhang JZ (2000). Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology 55: 397–404.
